1 citations
,
September 2025 in “Frontiers in Immunology” This study reviewed the expression of chemokines in patients with alopecia areata, finding elevated Th1 and Th2 chemokine levels, suggesting a complex immune profile that may require broad immunomodulatory strategies to address the disease's underlying immune dysregulation.
3 citations
,
September 2025 in “Frontiers in Immunology” This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.
8 citations
,
May 2025 in “British Journal of Dermatology” This study found that the psychosocial impact of AA is more strongly related to patients' illness perceptions and stigma than to the severity of the disease.
April 2025 in “Skin Appendage Disorders” This review highlights the potential role of vitamin D and its analogs in managing alopecia areata, noting that vitamin D deficiency and altered receptor expression may be linked to disease severity and that supplementation could help reduce severity and relapse rates.
1 citations
,
August 2024 in “Archives of Dermatological Research” In this case-control study using the All of Us database, no significant association was observed between alopecia areata and venous thromboembolism after controlling for hypercoagulable risk factors.
May 2024 in “Journal of cosmetic dermatology” In this retrospective study, oral tofacitinib treatment for at least 6 months improved scalp hair loss in 69.1% of alopecia areata patients, with patchy AA cases responding better compared to other subtypes, and no significant adverse effects were reported.
December 2023 in “International Journal of Molecular Sciences” In this study, researchers found that young men with androgenic alopecia exhibited significantly higher mRNA levels of 5α-reductase isozymes and changes in prostate cancer-related genes, which could explain varying responses to treatment and guide future therapies.
1 citations
,
October 2023 in “British journal of dermatology/British journal of dermatology, Supplement” This study found that, in Germany between 2016 and 2020, alopecia areata had an annual prevalence of 210 cases per 100,000 and an incidence of 72 cases per 100,000, with higher rates in specific regions and associated with comorbidities like atopic dermatitis and psoriasis.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
2 citations
,
January 2023 in “Dermatology practical & conceptual” This study shows that Covid-19 infection significantly impacts the emergence of new-onset hair diseases, with a notable association reported between having Covid-19 and developing hair issues.
1 citations
,
January 2023 in “Revista Da Associacao Medica Brasileira” This study found that patients with seborrheic dermatitis were more likely to have severe vitamin D deficiency compared to healthy controls.
59 citations
,
June 2022 in “Frontiers in medicine” This review discusses the complex causes and treatment challenges of chronic inflammatory skin diseases, emphasizing the need for biomarkers to predict treatment responses; it reports no new clinical results.
16 citations
,
January 2022 in “International journal of molecular sciences” This review summarizes the influences of lifestyle factors such as smoking, alcohol, and diet on the pathogenesis of alopecia areata but reports no new clinical results.
34 citations
,
July 2020 in “Dermatologic Therapy” This study observed increased online searches for "acne," "eczema," and "hair loss" but decreased interest in "botox," "skin cancer," and some other terms during the COVID-19 pandemic in Turkey and Italy.
8 citations
,
January 2020 in “Indian Dermatology Online Journal” In this study, PRP injections showed comparable effectiveness to triamcinolone for alopecia areata, with a significant decrease in SALT score at one interval, and 12.5% of patients in the PRP group experienced excellent hair regrowth compared to none in the triamcinolone group.
26 citations
,
January 2017 in “Acta dermato-venereologica” This review examines the use of monoaminergic antidepressants for inflammatory skin disorders and reports they may reduce dermatological symptoms, suggesting a potential role beyond treating psychiatric conditions.
144 citations
,
July 2015 in “Clinical, Cosmetic and Investigational Dermatology” This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.
275 citations
,
November 2002 in “International Journal of Dermatology” This study found that among an Asian population with alopecia areata, commonly first episodes occurred before age 40, with severe cases linked to psychological effects and treatments showing significant regrowth.
